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Abstract
Background: Many breast cancer patients remain free of distant metastasis even without adjuvant
chemotherapy. While standard histopathological tests fail to identify these good prognosis patients
with adequate precision, analyses of gene expression patterns in primary tumors have resulted in
more successful diagnostic tests. These tests use continuous measurements of the mRNA
concentrations of numerous genes to determine a risk of metastasis in lymph node negative breast
cancer patients with other clinical traits.
Methods: A survival model is constructed from genes that are both connected with relapse and
have expression patterns that define distinct subtypes, suggestive of different cellular states. This in
silico study uses publicly available microarray databases generated with Affymetrix GeneChip
technology. The genes in our model, as represented by array probes, have distinctive distributions
in a patient cohort, consisting of a large normal component of low expression values; and a long
right tail of high expression values. The cutoff between low and high expression of a probe is
determined from the distribution using the theory of mixture models. The good prognosis group
in our model consists of the samples in the low expression component of multiple genes.
Results: Here, we define a novel test for risk of metastasis in estrogen receptor positive (ER+)
breast cancer patients, using four probes that determine distinct subtypes. The good prognosis
group in this test, denoted AP4-, consists of the samples with low expression of each of the four
probes. Two probes target MKI67, antigen identified by monoclonal antibody Ki-67, one targets
CDC6, cell division cycle 6 homolog (S. cerevisiae), and a fourth targets SPAG5, sperm associated
antigen 5. The long-term metastasis-free survival probability for samples in AP4- is sufficiently high
to render chemotherapy of questionable benefit.
Conclusion: A breast cancer subtype defined by low expression of a few genes, using a minimum
of statistical modeling, has significant prognostic power. This test is of potential clinical benefit in
deciding a course of treatment for early stage breast cancer patients.
Background
The decision to use adjuvant chemotherapy to treat early
stage breast cancer must balance the reduced risk of recur-
rence with chemotherapy's toxic effects. The National Sur-
gical Adjuvant Breast and Bowel Project trials B-14 and B-
20 suggest that 85% of node-negative, ER+ patients who
are treated with tamoxifen alone will be disease free for 10
years [1]. Treatment guidelines such as those from the St.
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of patients who can safely forgo chemotherapy; however
under these guidelines, a significant number of patients
undergo chemotherapy unnecessarily.
In recent years, methods of stratifying breast cancer
patients according to relapse risk have been developed
using multi-gene measures of mRNA concentrations. Two
tests in current clinical use are the 21-gene screening
panel, Oncotype DX [4,5] (Genomic Health, Redwood
City, CA), and the 70-gene array-based test Mammaprint
[6,7] (Agendia, Amsterdam). These tests apply to node-
negative tumors with various other histopathological
traits. The prospective clinical trial TAILORx [8,9] is test-
ing the ability of Oncotype DX to identify patients who
can safely forgo chemotherapy. The MINDACT trial in
Europe is a similar test of Mammaprint [9,10]. Oncotype
DX is used to compute the recurrence score [4], which is a
linear combination of the expression levels of 16 genes.
Patients are classified as low, intermediate or high risk
using cutoffs of the recurrence score. Mammaprint is
implemented with a custom microarray. The partition of
patients into good and poor prognosis groups was origi-
nally accomplished by clustering with the expression val-
ues of 70 genes. Both of these tests utilize continuous
measurements of mRNA concentrations of numerous
genes.
The accelerated progression relapse test, developed here, uti-
lizes genes that are not only connected to survival, but
have expression patterns that define multiple subtypes,
suggestive of distinct cellular states. Distinct expression
patterns in two sets of patients suggest that different bio-
logical pathways may be active. Our approach is analo-
gous to the familiar separation of breast cancer tumors
into ER+ and ER- groups. The difference between the two
groups is more than a change along a continuum; differ-
ent processes are active in the two groups. Moreover, there
is significant evidence that cancer in humans progresses
through a series of discrete steps reflecting genetic altera-
tions [11,12]. Genes with expression patterns that divide
patients into two subtypes, one of which is enriched with
poor prognosis patients, may be the most direct markers
of disease progression.
A method akin to clustering, known as mixture models, is
used to identify genes that define distinct subtypes. Unsu-
pervised clustering is a familiar method of deriving sub-
types from microarray data of cancer samples [13-15].
These applications use measures of tens or hundreds of
genes. Here, we cluster samples using one gene at a time,
much like the classification of samples as ER+ or ER-,
ERBB2+ or ERBB2-, etc., utilizing only genes that define
distinct subtypes in multiple patient cohorts. Such genes
are called multi-state in this paper, and defined formally
with mixture models in the Results section. Just as with ER
status, for a multi-state probe p there is a threshold c such
that the samples with expression values above c, denoted
p+, form one component, and the samples with expres-
sion values below c, denoted p-, form the second compo-
nent. Figure 1 plots the density distributions in one cohort
of the four multi-state probes used in our prognostic test.
In this paper, one component of a multi-state probe is
approximately normally distributed and the other con-
sists of a tail to the right or left.
The accelerated progression relapse test is developed using
the multi-state probe methodology. The 4 probes men-
tioned in the abstract are multi-state, and positively corre-
lated with relapse, across independent cohorts. The good
prognosis group in the accelerated progression test, AP4-,
consists of the samples in the low expression component
for each of the 4 probes. The remaining samples comprise
the AP4+ group. In the union of 4 independent datasets,
not used to derive the subtype, the hazard ratio for distant
metastasis between AP4+ and AP4- is 3.76 (95% CI 2.16
– 6.56). The 10-year metastasis-free survival probability
for the AP4- group is 0.89 (95% CI 0.85 – 0.93), making
systemic chemotherapy of questionable benefit.
Methods
Patient cohorts and data analysis
The microarray datasets used here were obtained from the
Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/
geo/, specifically, GSE4922 (UPPS), GSE6532 (OXFD,
GUYT), GSE7390 (TRANSBIG), GSE9195 (GUYT2), and
GSE11121 (MZ). The codes used for the cohorts in this
paper are given in parentheses. Two independent cohorts
were obtained from GSE6532, for a total of 6 cohorts,
with 813 ER+ samples. The OXFD cohort is the combina-
tion of OXFT and OFXU from GSE6532. (GSE6532 con-
tains additional cohorts, coded KIT and KIU, however
these cohorts were excluded since many of the patients in
these groups are also found in GSE4922.) None of the
patients received adjuvant chemotherapy. A summary of
the clinical traits of the patients is found in Table 1. Com-
plete descriptions can be found in the references at the
Gene Expression Omnibus. Only the estrogen receptor
positive tumors were used in this study. Estrogen receptor
status was determined here from the microarray data,
since the clinical status was assessed by different methods
across the cohorts. A "+" after the code for a cohort
denotes the set of ER+ samples. In all cohorts, the survival
endpoint used was distant metastasis, except in GSE4922,
in which it was local recurrence or metastasis. Data on
metastasis for most of the samples in this cohort are found
in GSE6532. All survival data was censored to 10 years so
as not to distort the data due to different study lengths. In
each cohort, the mRNA was extracted from primaryPage 2 of 16
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The density distributions of the probes in AP4 divide into high and low componentsFigur  1
The density distributions of the probes in AP4 divide into high and low components. The expression values are for 
the four probes from the ER+ samples in the TRANSBIG cohort. The density distribution of each probe shows a large compo-
nent with low baseline expression and small standard deviation, and a long right tail with elevated expression. The mixture 
model method applied here calculates cutoffs between the two components, indicated by the dotted vertical lines. In each case, 
the high component is significantly enriched with metastatic cases. The ratios of the low components are: CDC6, 0.95; MKI67 
(212022_s_at), 0.85; MKI67 (212020_s_at), 0.89; SPAG5, 0.85. The ratio cutoff for being considered a multi-state probe 
in this cohort is 0.83.
BMC Cancer 2009, 9:243 http://www.biomedcentral.com/1471-2407/9/243tumors and hybridized to an array from the Affymetrix
GeneChip platform hgu133a or hgu133plus2.
The language R http://www.r-project.org/ was used for all
statistical analyses. Survival models were fit with the R
package survival. The proportional hazard condition was
verified with the cox.zph function. All p-values in sur-
vival models refer to the p-value of the logrank score of a
Cox proportional hazard model (CPH). A CPH is consid-
ered statistically significant if the p-value of the logrank
score is < 0.05.
Mixture models
Given a numeric vector, the statistical method of finite
mixture models partitions the vector into components,
each of which is modeled by a different density distribu-
tion. The mixture models used in this paper fit a pair of
gaussian distributions to a vector. Such a model is
described by a partition of the vector into components C1,
C2, and a pair of gaussian distributions g1, g2 modeling the
distributions of C1, C2, respectively. The modeling process
simultaneously partitions the vector and selects the
means, μ1, μ 2 and standard deviations σ1, σ2 of the two
gaussian distributions, with the goal of giving the best
possible fit over all alternatives. The fitting algorithm
actually produces, for each point and component, a pos-
terior probability that the point is in that component. The
point is assigned to the component whose associated pos-
terior probability is maximal.
For a point p that is well-classified in, say, component 1,
the posterior probability that p is in C2 will be very small.
For convenience, posterior probabilities below a thresh-
old δ are reported as 0. Following [16], we use δ = 10-4.
Points that are on the boundary between the two compo-
nents will have posterior probability > δ for both compo-
nents. The "isolatedness" of, e.g., component 1 is assessed
by the ratio, r1 = n1/m1, where n1 is the size of C1 and m1 is
the number of elements with posterior probability of
belonging to C1 greater than δ. Ratios are ≤ 1, with num-
bers close to 1 representing well-isolated components.
Ratios will be used in this paper to measure the ability of
a mixture model fit to describe distinct states.
In most instances, the components defined by a fit of a
pair of gaussian distributions consist of a pair of unbroken
intervals. That is, there is a cutoff c so that one component
consists of the values <c and the other component the val-
ues ≥ c. In this way, mixture models can be used to calcu-
late a threshold for dividing a vector into high and low
components.
A standard measure of the quality of a mixture model fit
is the likelihood, which is the product, over all points, of
the maximal posterior probabilities. The likelihood can
be used to decide, for example, if a fit with a pair of gaus-
sian distributions is better than a fit with a single gaussian,
or if a fit with Gamma distributions is better than a fit with
gaussian distributions. Even better measures are AIC and
BIC which adjust likelihood by the degrees of freedom.
Table 1: Summary of the patient cohorts used in this study
Uppsala Transbig Guys 1 Oxford Guys 2 Mainz
Code UPPS TRANSBIG GUYT OXFD GUYT2 MZ
GEO Series GSE4922 GSE7390 GSE6532 GSE6532 GSE9195 GSE11121
array hgu133a hgu133a hgu133plus2 hgu133a hgu133plus2 hgu133a
# samples 249 198 87 178 77 200
# ER+ 200 138 85 144 77 169
LN+/-/? on ER+ 62/132/6 0/138/0 56/29/0 36/102/6 36/41/0 0/169/0
Tamoxifen ? ? 85 105 77 ?
Grade 1/2/3/? on ER+ 64/110/26/0 29/72/36/1 17/37/15/16 25/63/22/34 14/20/24/19 29/123/17/0
< 2 cm/≥ 2 cm on ER+ 95/105 54/84 30/55 56/88 28/49 88/81
LN+/-/? = lymph node status; positive, negative, missing
Tamoxifen = number of patients receiving tamoxifen
< 2 cm/≥ 2 cm = the diameter of the tumorPage 4 of 16
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multi-state probe.
In this paper, mixture models were fit using the flexmix
[16]R package.
Results
The results in the paper consist of both the development
of the multi-state probe methodology for survival models,
and the application of this method to breast cancer.
Multi-state probe methodology for survival models
GCRMA is used to calculate expression values
Expression values are computed from the CEL files with
gcrma [17]. Many of the genes central to proliferation are
unexpressed or expressed at a low baseline level in normal
tissue. Given the prominent role played by proliferation
in breast cancer progression, it is important to measure
low concentration mRNA levels as precisely as possible. It
was shown in [18] with spike-in data that gcrma has supe-
rior accuracy and precision to other methods in measur-
ing low concentration mRNA. The effect on the AP4
model of using MAS5 instead of gcrma is described in the
Discussion section.
Note that gcrma is applied separately to each of the 6
microarray datasets. Expression values in different data-
sets are never compared to each other. This allows us to
include in the study datasets based on both hgu133a and
hgu133plus2. A binary variable for each probe in the
AP4 model is calculated as a step in forming the AP4 par-
tition in a dataset. Whether a sample has a value 0 or 1 is
based only on the probe's expression values within the
dataset. In studying properties of the AP4 model we do
merge the datasets of binary variables. This allows us to
reference, e.g., one large validation dataset that is the
union of four cohorts.
Multi-state probes are defined with mixture models
As motivated in the Background section, distinct gene
expression patterns are used here to model distinct bio-
logical states. At a basic level, mixture models can be fit to
expression vectors to identify these different states. How-
ever, the natural variation in expression patterns makes it
a challenge to decide which fits to multiple distributions
represent distinct states and which are simply anomalies
in the data. The fact that most microarray databases con-
tain fewer than 200 samples accentuates the problem. In
a preliminary study we found that, ranging over a large set
of probes in one microarray database, for all but a few
probes, a fit with a pair of gaussian distributions has
higher likelihood than a fit with a single distribution
(either gaussian or Gamma). A more stringent measure
than likelihood is needed to separate those patterns that
represent distinct states from noise. The phenotype we are
trying to model will guide the definition of a multi-state
probe.
Let x denote the expression vector of a gene such that
increased expression is positively correlated with relapse
in a cohort of ER+ breast cancer patients. Suppose that a
fit to a pair of gaussian distributions produces two com-
ponents, consisting of the values above a threshold c and
the values below c. The high component will be enriched
with metastatic cases. For a gene that significantly influ-
ences metastasis, many of the samples in the high compo-
nent will be metastatic. In a representative cohort only
about 25% of the patients eventually metastasize, so the
high component is likely much smaller than the low good
prognosis component. Instead of appearing as a pair of
components of equal size, it is modeled by a large normal
component and a right tail of elevated values. The degree
of separation of the tail from the low component is a
measure of the quality of this fit. Referring to the parame-
ters described above, this suggests that a high value for the
ratio of the low component indicates a gene with distinct
states. For a gene y that is negatively correlated with
relapse, the high component is the good prognosis group
and the low component is enriched with metastatic cases.
In analogy with x, the ratio of the high component of y
measures the quality of this fit. In either case, the ratio of
the good prognosis component is the important parame-
ter. This is the motivation behind the following defini-
tion. Also see Figure 1.
Given a microarray database S, let Y be a large set of
probes that are correlated with relapse. For each probe p in
Y, fit a pair of gaussian distributions to the expression vec-
tor for p in S, and let rp be the ratio of the good prognosis
component. Let r0 be the median of rp, for p in Y. A probe
p in Y is multi-state in S if rp > r0.
The density distributions of the four probes in AP4 in the
TRANSBIG+ cohort are plotted in Figure 1, along with the
cutoffs between high and low components and indicators
for metastatic cases.
An adjustment to the mixture model process is required
for a probe whose distribution can be modeled with a pair
of gaussian distributions in multiple ways, or when the
components are broken intervals. This occurs when, as in
Figure 1(c), the optimal fit is with 3 gaussian components
instead of 2. However, routinely fitting expression vectors
with more than 2 gaussian distributions risks over fitting
the data. It is rare for the 3 component fit to be optimal
across multiple cohorts. Instead, for a vector positively
correlated with relapse we remove from the vector the
lowest 10% of values prior to fitting with a pair of gaus-
sian distributions. For a gene negatively correlated with
relapse we trim the highest 10% of values. This correctionPage 5 of 16
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and does not effect the cutoff between components for
other probes.
The parameters for the pair of gaussian distributions can
be used to illustrate the quality of the fit for multi-state
probes in specific datasets. Let Y be the 100 most signifi-
cant probes in the UPPS+ cohort, as described below in
the derivation of AP4. The median ratio of good prognosis
components for this set is 0.89. Let x be the expression
vector of a multi-state probe positively correlated with
relapse, gL, gH the gaussian distributions of the low and
high components, μL, μH and σL, σH the means and stand-
ard deviations of gL, gH, respectively, and c the cutoff
between the low and high components. We find empiri-
cally, that for any such x that is multi-state, μH - μL > 5σL
and c - μL > 2.8σL. That is, all elements of the high compo-
nent are above the 0.997 quantile of gL. This shows a high
degree of separation between the components.
It is worth noting that, in some instances, a fit with a pair
of Gamma distributions has a higher likelihood than a fit
with gaussian distributions. However, checking the multi-
state probes in one cohort in the study, the components
defined by Gamma distributions and gaussian distribu-
tions are exactly the same for half of the probes and never
differ by more than 2%. Thus, we choose to work only
with the simpler gaussian distributions.
The mixture model methodology recognizes subtypes
To test the effectiveness of the multi-state methodology to
define subtypes, it is applied to the estrogen receptor 1
gene, ESR1, to model ER status. In [19] it was shown that
a partition of samples based on expression values of the
probe p = 205225_at yields about 90% agreement with
ER status, as assessed by immunohistochemistry (IHC). In
[19], the threshold between high and low expression of
the probe was determined by a fit to ER status in a training
set. Here, the above mixture model methodology was
applied to the expression vector of the probe p in the
TRANSBIG cohort to find p- and p+ components. Agree-
ment with the clinically assessed ER status was compared.
This process was repeated with 1, 000 subsets of TRANS-
BIG, each consisting of 2/3 of the samples. The accuracy of
the mixture model approximation was 0.88 (95% CI
0.85–0.92). At the same time, possible cutoffs for p were
surveyed and the maximum accuracy was recorded for
each of the 1, 000 subsets. The maximum accuracy of a p
expression cutoff to reproduce ER status was 0.89 (95% CI
0.86 – 0.92). Similar results were obtained in OXFD. See
Figure 2.
Thus, the mixture model approach to dividing samples
into low and high components of ESR1 expression, based
solely on the distribution of expression values, gives
nearly optimal agreement with ER status as assessed by
IHC.
Survival model development focuses on good prognosis patients
Reflecting the position that the +/- status of a multi-state
probe is as informative as the raw expression values,
multi-state probes will be represented in survival models
as binary variables: 0 for the good prognosis component,
and 1 for the other. For X a multi-state probe or corre-
sponding binary variable, gd(X) denotes the good progno-
sis group of samples. For a probe positively correlated
with relapse, gd(X) is the low expression component.
Survival models using multiple multi-state probes are
defined to focus on the good prognosis samples. The par-
tition of samples generated by a set of multi-state probes
X1,...,Xn distinguishes the samples in gd(Xi), for all i, from
the rest. Identifying the Xi with binary variables, this parti-
tion is defined by the binary variable Y that is 0 when
every Xi is 0, and 1 otherwise. Y is denoted X1 ** Xn. The
survival model generated by X1,...,Xn is a model whose
sole variable is the binary variable X1 ** Xn. Under this
approach, a sample that is in the high-risk component for
any variable is high risk overall. Gradations of risk in the
Density distribution of ESR1 compared to ER statusFigure 2
Density distribution of ESR1 compared to ER status. 
Mixture models applied to the ESR1 gene accurately model 
the clinically assessed ER status. The dotted line indicates the 
cutoff between high and low components as found by fitting 
the density distribution with a pair of gaussian distributions. 
The accuracy of the approximation of ER status by the high 
and low components is 0.88 (95% CI 0.85 – 0.92), as deter-
mined by Monte Carlo cross-validation.Page 6 of 16
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probes are not part of this study. For Y the * product of
multi-state probes, gd(Y) is the set of samples on which Y
is 0.
Given a set P of multi-state probes and a sample cohort S,
an optimal survival model derived from P is defined with
a binary variable Y such that (1) Y = X1 ** Xn, for some
X1,...,Xn in P, (2) on gd(Y) no CPH using a single Z in P is
significant, and (3) no variable Y' that is the * product of
a proper subset of X1,...,Xn satisfies (2). Less formally,
gd(Y) is the largest set that is the intersection of good prog-
nosis sets defined with elements of P, and which cannot
be significantly improved by intersecting with a further
element of P.
While multi-state probes are represented by binary varia-
bles, other probes can be tested for significance as contin-
uous expression vectors. This is a routine step in finding
an optimal model by this method. In this way, no infor-
mation is lost by first considering some probes as binary
variables.
The AP4 test for metastasis in ER+ breast cancer
Derivation of the AP4 model
The AP4 model is derived with the ER+ samples in two
cohorts as training sets, GSE4922 (denoted UPPS+) and
GSE7390 (TRANSBIG+). An initial set of 100 significant
probes is identified as follows: Working in UPPS+, 100
training sets are selected, each containing 2/3 of the sam-
ples that relapse and 2/3 of the samples that do not
relapse. For each training set and each probe p, a CPH is
computed using as its sole variable the expression vector
of the probe restricted to the training set. For each training
set, the 100 most significant probes, as measured by the
logrank score p-values, are selected. Finally, let Y be the
100 probes that occur most frequently in the top 100
probes for these training sets.
A set of probes to serve as candidates for inclusion in the
model is selected from Y as follows: Let Yup be the probes
in Y that are positively correlated with relapse. Let Pup be
the probes p in Yup such that (1) p is multi-state in both
UPPS+ and TRANSBIG+, and (2) the binary variable rep-
resenting p is significant in a CPH in UPPS+ and TRANS-
BIG+. A set Pdn of probes negatively correlated with
relapse is derived correspondingly. The set of candidate
probes P is the union of Pup and Pdn. Executing this proce-
dure yields a set of 16 probes.
An optimal survival model derived from P in UPPS+ is
generated by CDT1 (209832_s_at), SPAG5
(203145_at), CDC6 (203967_at), and SNRPA1
(216977_x_at). In TRANSBIG+ an optimal survival
model derived from P is generated by MKI67
(212020_s_at), SPAG5 (203145_at), PLK1
(202240_at), SNRPA1 (216977_x_at), and MKI67
(212022_s_at). In both cases the probes are all posi-
tively correlated with relapse, hence the good prognosis
group for any probe is the low expression component. As
the initial model, called AP7, we choose the one generated
by the 7 probes obtained from either cohort. This ensures
that samples in AP7- in both UPPS+ and TRANSBIG+
have good prognosis. While the process identifies AP7,
models generated by fewer of these probes perform as well
in the 6 cohorts in this study. One of these tests is AP4,
using 212020_s_at (MKI67), 212022_s_at (MKI67),
203967_at (CDC6), and 203145_at (SPAG5). For the
cohorts in this study, refining AP4- to the smaller AP7-
removes very few metastatic cases.
No continuous expression vector of a probe in Y is signif-
icant in a CPH on the subset AP4- in both UPPS+ and
TRANSBIG+. That is, no continuous expression vector
improves on the model defined discretely using the multi-
state probes. Similarly, no multi-state probe negatively
correlated with relapse improves this model.
Definition of the accelerated progression subtype in an arbitrary 
cohort
Given a microarray dataset for ER+ breast cancer tumors S,
based on the Affymetrix platform hgu133a or
hgu133plus2, the accelerated progression subtype is
defined as follows:
1. For each of the four probes 212020_s_at
(MKI67), 212022_s_at (MKI67), 203967_at
(CDC6), and 203145_at (SPAG5), apply the multi-
state probe methodology to divide the samples into
high and low components.
2. Define AP4- to be the samples in the low compo-
nent for each of the four probes; a sample is AP4+ if it
is in the high component for any of the probes.
The terminology reflects the viewpoint that samples in
AP4+ have elevated expression of genes that accelerate cell
cycle progression; AP4- samples have baseline expression
of these genes.
AP4 is a significant predictor of metastasis in independent cohorts
The AP4 model is validated in the four independent
cohorts, OXFD+, GUYT+, GUYT2+ and MZ+, none of
which is used to derive the model. The performance statis-
tics for the model in each cohort are reported in Table 2.
The mean 10-year metastasis-free survival probabilities of
the AP4- groups is 0.92, and AP4 is statistically significant
in three of the four cohorts. The binary variables defining
AP4 in each cohort are merged to form a single variable
ranging over the union of the four cohorts. A Kaplan-Page 7 of 16
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in Figure 3.
The AP4 test improves on the prognostic power of each of
the individual probes in the test. A preliminary step in cal-
culating AP4 is a partition of the samples in a cohort into
CDC6 +/-, MKI67 +/-, etc. The binary variables represent-
ing these partitions can be merged to represent partitions
for each probe ranging over the full validation set. The
Kaplan-Meier plots for each probe, juxtaposed with the
AP4+/- plot, are found in Figure 4. While each probe
yields a significant partition, none of the probes is as sig-
nificant as AP4, as measured by the hazard ratio.
The classification of a sample as AP4- or AP4+ is stable across 
reference sets
In a generalization of the AP4 test beyond this study a new
sample would be classified as AP4+ or AP4-using cutoffs
defined with a reference set of samples. The stability of
these cutoffs is tested with the following Monte Carlo
cross-validation method. Given a microarray dataset for a
cohort S and a subset of samples S0 balanced for relapse,
thresholds are determined for the 4 probes in AP4 using
the expression vectors restricted to S0. A sample not in S0
is classified as AP4+ or AP4- using the cutoffs defined in S0
and this status is compared to that calculated using all of
S. We associate to S0 the fraction of correctly classified
samples. The accuracy of the cutoff estimation is the mean
value over a large number of subsets like S0. In this study
we use 1, 000 subsets.
The accuracy of the reference set prediction of AP4 status,
calculated across all cohorts, is 0.97 (95% CI 0.88 – 1.00).
This high degree of stability is likely due to the intrinsic
nature of the cutoffs.
AP4 improves on the prognostic power of clinical variables
A biomarker for relapse is only useful if it improves on the
prognostic power of the standard clinical variables, such
as tumor grade, size and lymph node status. We show that
AP4 is significant in multivariate analysis and in stratified
analysis on clinically defined subtypes. This study is per-
formed on the 738 samples in the study for which data is
available on distant metastasis, tumor grade, size and
lymph node status. Tumor size is represented here by a
binary variable that is 0 for tumors < 2 cm in diameter and
1 for tumors ≥ 2 cm.
The AP4 test improves on the clinical variables in a multi-
variate Cox proportional hazard model. The p-values for
the clinical variables in univariate models are: grade, p =
Kaplan-Meier survival plot for AP4 in the validation setFigure 3
Kaplan-Meier survival plot for AP4 in the validation 
set. The validation set consists of the ER+ samples in the 
cohorts OXFD, GUYT, MZ and GUYT2, totalling 475 
patients. The 5 and 10-year metastasis-free survival probabil-
ities for the AP4- group are 0.95 (95% CI 0.92 – 0.98) and 
0.89 (95% CI 0.85 – 0.93), respectively. The corresponding 
probabilities for the AP4+ group are 0.77 (95% CI 0.73 – 
0.81) and 0.65 (95% CI 0.60 – 0.70). The hazard ratio 
between AP4+ and AP4- is 3.76 (95% CI 2.16 – 6.56).
Table 2: Performance of the AP4 relapse test in validation cohorts








OXFD+ 38% 0.96 (0.90 – 1.00) 0.93 (0.86 – 1.00) 6.73 (2.02 – 22.4) 3 × 10-4
MZ+ 47% 0.92 (0.86 – 0.98) 0.85 (0.75 – 0.95) 2.23 (1.02 – 4.87) 0.039
GUYT+ 31% 0.96 (0.89 – 1.00) 0.88 (0.76 – 1.00) 3.09 (0.90 – 10.5) 0.058
GUYT2+ 36% No metastases in AP4-
TOTAL 40% 0.95 (0.93 – 0.98) 0.89 (0.85 – 0.93) 3.76 (2.16 – 6.56) 5.14 × 10-7
The 5 and 10 year metastsis-free survival probabilities for the AP4- groups in the validation cohorts, the hazard ratio for AP4- to AP4+, and the 
logrank p-value.Page 8 of 16
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Kaplan-Meier survival plots for the individual genes in AP4Figure 4
Kaplan-Meier survival plots for the individual genes in AP4. The partition defined by each of the AP4 genes individually 
is a significant predictor of metastasis, however each is less significant than AP4. In (a), MKI67 denotes the probe 
212022_s_at and in (c), MKI67.2 denotes the probe 212020_s_at. The sample set is the same set used in Figure 3, 
namely, the union of the ER+ samples in OXFD, GUYT, MZ and GUYT2. The hazard ratios, with 95% confidence intervals, for 
these genes are: MKI67, 2.90 (1.84 – 4.57); CDC6, 2.47 (1.62 – 3.75); MKI67.2, 1.84 (1.20 – 2.82); SPAG5, 2.91 (1.92 – 4.43). 
These are significantly smaller than the hazard ratio of 3.76 for AP4.
BMC Cancer 2009, 9:243 http://www.biomedcentral.com/1471-2407/9/243
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Kaplan-Meier survival plot for AP4 in clinical subtypesFigure 5
Kaplan-Meier survival plot for AP4 in clinical subtypes. The domain for this analysis is the set of 738 samples for which 
data exists on distant metastasis, grade, tumor size and node status. Each plot is for AP4 in the subtype indicated above the 
panel.
BMC Cancer 2009, 9:243 http://www.biomedcentral.com/1471-2407/9/2435.6 × 10-5; node status, p = 0.02; size, p = 4.6 × 10-7. The p-
value for grade, node status and size together is 9.0 × 10-8,
while adding AP4 to these 3 gives p = 2.4 × 10-15. Compar-
ing log-likelihoods, the level of significance of AP4 over
grade + node status + size is 5.8 × 10-11. Note that the dis-
tribution of lymph node status in the full dataset is dis-
torted by the fact that some cohorts contain only node
negative samples (see Table 1).
AP4 is found to be statistically significant on each of the
subtypes defined individually by grade, size and lymph
node status. The Kaplan-Meier plots are found in Figure
5(a)–(g). Keeping in mind that the goal of this project is
to identify patients who may not benefit from chemother-
apy, good prognosis groups are formed by combining
clinical subtypes. AP4 is statistically significant on the set
of lymph node negative tumors that are < 2 cm in diame-
ter (Figure 5(h)). On the grade 2 tumors in this latter sub-
group the p-value for AP4 is not below the significance
threshold, however the Kaplan-Meier plot (Figure 5(i))
does show a pronounced divergence in expected survival
for AP4- and AP4+. Most of the sets formed by intersecting
three clinical subgroups are too small for meaningful
analysis. It is worth noting that the 10-year expected sur-
vival probability in AP4- is nearly constant across all of
these clinical subgroups, even poor prognosis groups such
as grade 3 or LN+.
These clinical variables do not improve on the prognostic
power of AP4-. In fact, tumor grade is not a significant pre-
dictor of metastasis on AP4- or on AP4+; i.e., the ability of
tumor grade to predict metastasis is completely captured
by AP4+/-. Lymph node status has the same relationship.
Tumor size is not a significant predictor of metastasis on
AP4-, but is significant on AP4+ (p-value = 7.56 × 10-6.)
Discussion
In this study, a discrete model for metastasis in ER+ breast
cancer was derived using genes that define intrinsic sub-
types. The good prognosis group in the model, AP4-, has
a high 10-year metastasis-free survival probability inde-
pendent of clinical traits such as tumor grade, size and
lymph node status. There is a high degree of stability in
the boundary between AP4- and AP4+, likely due to the
intrinsic nature of the cutoffs.
While a prospective trial is needed to verify that AP4-
patients do not significantly benefit from chemotherapy,
this hypothesis is supported by the data in Table 2 and
studies of chemo-sensitivity; i.e., the likelihood that a
tumor will respond completely to chemotherapy. The
NSABP B-20 trial [1] reports that ER+ node-negative
patients receiving cyclophosphamide, methotrexate,
fluorouracil and tamoxifen have a 12-year overall survival
probability of 0.87. This probability is comparable to the
AP4- 10-year metastasis-free survival probability of 0.89
(95% CI 0.85 – 0.93). However, it is important to know
that the AP4- tumors that eventually metastasize are not
those that will benefit the most from chemotherapy. The
genomic grade index (GGI) [20], a test for recurrence in
ER+ breast cancer that is highly enriched with cell cycle
progression genes, is also correlated with chemo-sensitiv-
ity [21]. As Figure 6(a) shows, only a few AP4- samples
have GGI values above the mean of 0. Moreover, TOP2A,
a target for anthracyclines [22], is expressed at a low level
throughout AP4- tumors, Figure 6(b). Thus, those tumors
that respond most favorably to chemotherapy because
they have high proliferation rates are likely to be AP4+.
This makes it less likely that chemotherapy will benefit the
AP4- patients.
The methodology leading to the AP4 test actually identi-
fies a family of models with comparable hazard ratios in
the samples used here. These alternatives use 4 to 7
probes, chosen from those defining AP4 and probes rep-
resenting CDT1 (chromatin licensing and DNA replica-
tion factor 1), PLK1 (polo-like kinase 1), CDC45L
(CDC45 cell division cycle 45-like (S. cerevisiae)), and
SNRPA1 (small nuclear ribonucleoprotein polypeptide
A'). Most of these genes are directly involved in mitosis,
consistent with the central role of cell cycle progression in
ER+ breast cancer relapse [20,23]. Reports of poor prog-
nosis in carcinomas with elevated expression of these
Comparison of AP4 and indicators of chemo-sensitivityFigure 6
Comparison of AP4 and indicators of chemo-sensitiv-
ity. The distribution of GGI (a) and TOP2A (b) across the 
AP4+/- groups suggests that chemo-sensitive tumors are 
AP4+. The plot for GGI was calculated in the ER+ samples in 
TRANSBIG, while the plot for TOP2A is from MZ. The GGI 
values were scaled to a mean of 0 and standard deviation of 
1.Page 11 of 16
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have been widely studied, the other gene in the AP4 test,
SPAG5 is less well-known. Also known as Astrin, SPAG5
codes a protein involved in mitotic spindle assembly.
Silencing of SPAG5 induces p53-mediated apoptosis and
sensitizes cells to paclitaxel treatment in HeLa cells [25].
In [28] it is shown that SPAG5 interacts with AURKA
(STK15). Both MKI67 and AURKA are found in the Onco-
type DX panel.
Using the results in this study, the AP4 test could be
implemented with a reference set of microarrays. A patient
would be tested by hybridizing mRNA from the tumor to
a microarray, applying gcrma to this microarray and the
reference set together, and determining the sample's AP4
status using cutoffs determined with the reference sam-
ples. However, full genome microarrays are comparatively
expensive and generate a huge amount of information
that is not used in determining AP4 status. The develop-
ment of a clinically useful form of the AP4 test requires (1)
Survival plots for AP4 in subtypes defined by proliferation markersFigure 7
Survival plots for AP4 in subtypes defined by proliferation markers. Here, the MKI67 +/- partition is used as a surro-
gate for the Ki-67 proliferation index. Combining this with tumor grade gives subtypes defined by clinical proliferation markers. 
The domain for this analysis is the same set of 738 samples used in the study of clinical subtypes. The subtypes are indicated 
above the panels. AP4 improves on the prognostic power of these subtypes, except on the small group of grade 3 tumors that 
are MKI67 -. AP4 is vacuous on MKI67 + since all such samples are AP4+.Page 12 of 16
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tion or protein levels of the associated genes, (2) analysis
of the density distribution of these measures and selection
of cutoffs using the mixture model method, and (3) deter-
mination of the long-term expected survival probability
for the AP4- group calculated using the cutoffs from (2).
While the most direct method would use RT-PCR or a cus-
tom microarray to measure the mRNA levels, it is likely
that some test in the accelerated progression family can be
implemented with IHC. This hypothesis is supported by
other studies of the genes in the accelerated progression
family. The Ki-67 proliferation index for a tissue sample is
the percentage of cells that respond positively to the MIB-
1 antibody using IHC, also called the labeling index for
Ki-67 [22,29]. The density distribution of Ki-67 labeling
indices in [[30], Figure 1] shows a pronounced tail to the
right, similar to gene expression for MKI67 (see Figure
1(b)). Refer also to results on CDC6 [31], CDC45L [26],
and PLK1 [27]. Such a test could use commonly available
formalin-fixed, paraffin-embedded tissue samples. We
anticipate validating this more clinically useful test in a
retrospective study on an independent set of samples.
An additional concern in focusing solely on the few genes
in this test is that the expression values in the microarray
datasets may be distorted by nonspecific binding of other
mRNA species to the Affymetrix probes. This problem
would reveal itself through a density distribution under
(2) that is very different from that found in the array data.
Whether this distortion occurs at a significant level can
only be determined through step (3) above.
Previous studies of several of the genes used in the accel-
erated progression family of models report that tumor tis-
sues have two distinct expression patterns of these genes,
supporting our multi-state methodology. Expression of
CDC6 in non-small cell lung cancer cells, as assessed with
RT-PCR, partitions cells into two groups; one with base-
line expression, and a second group with highly elevated
expression [[31], Figure 2]. Similar patterns were found
for CDT1 [31]. This same paper reports that IHC with an
antibody for CDC6 can also discriminate the low and
high expression states for that gene. Using IHC, PLK1 was
detected at a high level in invasive carcinomas of the
breast and undetected in normal breast tissue [27].
Although the genes comprising the AP4 test are central to
mitosis, the test apparently improves on the prognostic
power of common proliferation markers such as the Ki-67
proliferation index and tumor grade. Indeed, the presence
Comparison of models defined with gcrma and MAS5Figure 8
Comparison of models defined with gcrma and MAS5. Microarray data from a set of 125 samples in TRANSBIG+ was 
normalized with both gcrma and MAS5 on a log2 scale. In (a) the samples were rank ordered by gcrma expression values of 
MKI67 (212022_s_at) and these values are plotted. The log2 MAS5 expression values for these samples are also plotted. 
The red line indicates the +/- cutoff for the gcrma values and the blue line the cutoff for MAS5 values, as calculated by the 
multi-state methods. The calculation of AP4 is completed on both sets of expression values to produce gcrma and MAS5 ver-
sions of the test. (b) The Kaplan-Meier plots for the two versions of AP4 are given. The gcrma version of the test has a hazard 
ratio of 8.83 (95% CI 3.06 – 25.2), while the MAS5 version has a hazard ratio of 4.67 (95% CI 1.62 – 13.5).Page 13 of 16
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requires validating that the test has greater prognostic
power than Ki-67. Here, AP4 is compared to a prolifera-
tion indicator using the MKI67 +/- partition (using
212022_s_at) as a surrogate for the Ki-67 proliferation
index. On the good prognosis group MKI67 -, the p-value
of AP4 is 6.27 × 10-6 (Figure 7(a)). The Kaplan-Meier plots
of AP4 on the grade 1, 2 and 3 tumors in MKI67 – (Figure
7(b)–(d)) show that AP4 is significant in all of these sub-
types, except for the grade 3, MKI67 -, tumors. This latter
group contains only 35 samples.
The Oncotype DX test utilizes genes involved in processes
besides proliferation, however the dominance of prolifer-
ation genes in ER+ breast cancer progression is widely
reported [20,23]. The 16 genes in the Oncotype DX panel
are grouped as proliferation genes, tumor invasion genes,
those related to HER2 and estrogen, and three others. Cer-
tainly, processes besides proliferation contribute to breast
cancer metastasis, however this does not indicate that pro-
liferation markers are improved by additional genes.
A comparison with the proliferation group in Oncotype
DX suggests that AP4 contains significantly more prognos-
tic power than that group. The contribution of the prolif-
eration genes to the Oncotype DX recurrence score is
modeled here by the mean of the expression values of the
probes 202095_s_at (BIRC5), 212022_s_at (MKI67),
201710_at (MYBL2), 214710_s_at (CCNB1),
204092_s_at (AURKA), which we call the proliferation
score (see [[4], Figure 1]). To compare this surrogate pro-
liferation score with AP4, we find the high-low partition
of the score that best approximates the AP4+/- partition.
These binary proliferation scores, for each of the four val-
idation cohorts, are concatenated to form a binary varia-
ble, ranging over the entire validation set. Comparing
CPH models using the binary proliferation score alone,
and this variable together with AP4, shows that AP4 sig-
nificantly improves on the binary proliferation score with
a p-value of 2.37 × 10-5. Thus, even though the genes
defining AP4 are central to proliferation they seem to con-
tain significantly more information about metastasis than
the proliferation group in Oncotype DX.
Using gcrma rather than the more common MAS5 to cal-
culate expression values gives a more powerful AP4 test.
The genes in the accelerated progression family are unex-
pressed or expressed at a low baseline level in normal
breast tissue, so accurate and precise measurements of low
mRNA concentrations are important. It was shown in [18]
that gcrma is more precise than MAS5 in measuring
mRNA at low concentration levels. To explore this issue
we normalize 125 samples in TRANSBIG+ with MAS5 and
apply the mixture model methods to calculate thresholds
for the AP4 genes and a MAS5 version of the AP4+/- par-
tition. In Figure 8(a) expression values for MKI67
(212022_s_at) computed with gcrma are plotted in
increasing order, along with the values computed with
MAS5, on a log2 scale, and the cutoffs for MKI67 +/- under
both methods. As the figure shows, MAS5 measures for
samples that have low gcrma values, have significantly
higher variance. Many of these samples are classified as
MKI67 + under MAS5. Similar behavior is found in the
other AP4 probes. Under MAS5, 50 samples are AP4- and
all but one of these are AP4- under gcrma. However,
gcrma classifies an additional 18 samples as AP4-. As Fig-
ure 8(b) shows, the long-term expected survival of the two
AP4- groups are comparable. Thus, gcrma is able to iden-
tify significantly more good prognosis patients than
MAS5.
Studies of Oncotype DX and Mammaprint report that the
good prognosis groups they predict consist of 40% to 50%
of the study population [7,32]. The AP4- group in the val-
idation set consisting of the ER+ samples in OXFD, GUYT,
GUYT2 and MZ contains 40% of the samples. However,
Mammaprint and Oncotype DX are only administered to
node negative patients. Of the node negative samples in
the validation set, 43% are AP4-. In all node negative and
ER+ samples in this study, 49% are AP4-.
The properties of the expressed sequence tags (EST) tar-
geted by the two probes for MKI67 deserve further study.
The probe most significantly connected to relapse is
212020_s_at, which hybridizes the EST GenBank:
AU152107. This is transcribed from a continuous block of
DNA in Exon 1 of MKI67 (see UCSC Genome Browser
http://genome.ucsc.edu). The second probe, 212022_s at
targets GenBank: BF001806, transcribed from 3 blocks of
DNA in Exon1, Exon 2 and Exon 3. It is unclear whether
the corresponding mRNA code for different isoforms of
the MKI67 protein. The fact that they are both signifi-
cantly correlated to metastasis suggest that they both code
functional proteins. It is known that MKI67 is found in
multiple isoforms that effect cellular processes differently
[33].
Conclusion
The accelerated progression relapse test is defined using
few genes and a minimal amount of statistical modeling.
The thresholds between the low and high components of
the genes define stable subtypes correlated with metastasis
across independent cohorts. This test identifies a group of
ER+ tumors that are unlikely to respond to adjuvant
chemotherapy.
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